D2R | DNA to RNA is a research initiative at McGill University taking an inclusive Canadian approach to developing genomic-based #RNA therapies for rare diseases, infectious diseases and cancer.
www.mcgill.ca/dna-to-rna/
www.youtube.com/@D2RMcGill
D2R | DNA to RNA
Loading...
And that's a wrap on Day 1 of the #D2RSymposium2026 🎉 All of today’s sessions highlighted that the research, both within the D2R community and beyond, is full of exciting developments. Stay tuned for even more on Day 2 tomorrow!
#D2RProjectSpotlight: End to end sequencing platform for RNA therapeutics quality control (EESPRNATQC) Scientific Director: Ioannis Ragoussis (@mcgillu)🔗 Learn more here: buff.ly/zhzGYc7
🧬#D2RProjectSpotlight: Targeting miRNAs in Embryonal Brain Tumors (@mcgillu Prof. Jacek Majewski) This project will study the molecular effects of this genome rearrangement and explore the use of microRNA inhibitors – sponges – to counteract the oncogenic changes buff.ly/309J3d2
D2R | DNA to RNA
D2R | DNA to RNA
D2R awards nearly $6M in funding to support 4 Translational Impact research projects focused on advancing RNA-based therapies for cancer and rare genetic diseases. 🔗 Learn more about these projects and the funded professors here: buff.ly/TPzPPdH
🧬#D2RProjectSpotlight: Switchable self-amplifying RNA: Safe, Selective, and Programmable Therapeutic Expression led by Prof. Maureen McKeague with collaborator Prof. Anna Blakney 🔗Learn more here: buff.ly/hlfhhvb
#D2RSymposium2026 is underway! Sharing a few highlights from the action 📸 Tune into our LinkedIn for all the updates! 🧬 #RNATherapeutics
🌟 The #D2RSymposium2026 is officially underway! Today and tomorrow we will be posting highlights of the event on our LinkedIn including inspiring talks, innovative research, trainee presentations, and more in #RNAtherapeutics.💡Big MERCI to all our sponsors! buff.ly/YzOWyGL
🌟D2R is seeking a strategic and collaborative leader to join our team as Associate Director, Indigenous Health Research for D2R. This role supports Indigenous-led health research, fosters strong partnerships with Indigenous communities & organizations and more! Learn more: buff.ly/zxV3Uxx
Now in @natchem.nature.com: Antibodies dominate drug development—but they’re big, costly, and can trigger immune reactions. #McGill professors Hanadi Sleiman & Maureen McKeague introduce Alenomers: barcoded aptamers with antibody‑level chemical diversity, screenable at massive scale buff.ly/BKKN4zS
